C5 and atypical hemolytic-uremic syndrome: The C5a‐induced chemotaxis of proinflammatory cells could be restrained as well as the C5b‐induced membrane attack complex.35 ECZ was recommended in complement‐mediated diseases of atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and refractory generalized MG which could be unresponsive to GC and at least two immunosuppressive agents.24, 36 Notably, ECZ was employed in the two RCTs (ie, class I, Level A) for refractory generalized MG which may undervalue its genuine efficacy.